Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0381120070290030323
Genes and Genomics
2007 Volume.29 No. 3 p.323 ~ p.330
Thymidylate Synthase (TYMS) Tandem Repeat Polymorphism: As a Predictive Genetic Marker for the Risk of Alzheimer¡¯s Disease
Cho Sun-Young

Yang Hyun-Duk
Hwang Su-Jin
Yun Ji-Young
Kim Joon-Ki
Jo Beom-Ho
Chung Ki-Wha
Choi Byung-Ok
Abstract
Moderately elevated plasma homocysteine level is associated with an increased risk of Alzheimer¡¯s disease. Thymidylate synthase (TYMS) and 5,10-methylenetetrahydrofolate reductase (MTHFR) are involved in the homocysteine metabolic pathway. In this study, we tried to find the association between TYMS tandem repeat polymorphism and Alzheimer¡¯s disease. We analyzed the genotype of the TYMS and MTHFR C677T polymorphisms in 68 Alzheimer¡¯s patients and 413 healthy controls. The mean plasma homocysteine level was higher in Alzheimer¡¯s disease patients than in healthy controls (p < 0.05). Those subjects who carried at least one TYMS 2R allele [2R(+)] showed an increased risk of Alzheimer¡¯s disease (AOR, 2.09; 95%CI, 1.21-4.25). However, the MTHFR C677T polymorphism was not associated with an increased risk of Alzheimer¡¯s disease. In the comparison of the combinations of polymorphisms, the risk of Alzheimer¡¯s disease was highest in the subjects with the [2R(+)/T(+)] combined genotypes (AOR, 2.76; 95%CI, 1.30-6.71). In conclusion, particular genotype of TYMS tandem repeat polymorphism and combined genotypes of the TYMS tandem repeat and MTHFR C677T polymorphisms appeared to be predictive genetic biomarkers for the risk of Alzheimer¡¯s disease.
KEYWORD
thymidylate synthase, methylenetetrahydrofolate reductase, Alzheimer¡¯s disease, homocysteine
FullTexts / Linksout information
Listed journal information
SCI(E) ÇмúÁøÈïÀç´Ü(KCI)